Skip to main content
Caplight Logo









GV20 Therapeutics

GV20 Therapeutics

Private
Newton, MassachusettsHealthcare & Life Scienceshttps://gv20tx.com/

Last Round

Early Funding

Feb 1, 2025

Total Funding Raised

$30M

Company Overview

GV20 Therapeutics is a biotechnology company that develops antibody therapeutics for cancer treatment by integrating artificial intelligence, genomics, and cancer biology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

biotechnologydrug discoveryantibody therapeuticsoncologyai drug discoverycomputational biologyclinical-stage biotechtarget validationmulti-omicsrna-seqantibody-drug conjugateADCclinical trialsin silico drug discoverybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GV20 Therapeutics Comparables

Compare GV20 Therapeutics with similar companies based on industry and business-model similarity.

GV20 Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adcentrx Therapeutics
80%
Hummingbird Bioscience
78%
Generate Biomedicines
71%

GV20 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 1, 2025
Series BOct 14, 2021
Series AOct 2, 2018

Key People

Founding team and executive leadership

Xiaole Shirley Liu

Co-founder Chief Executive Officer

Founding Team

GV20 Therapeutics Investors

Notable investors and investment history

GV20 Therapeutics investors
InvestorRounds
IDG CapitalSeries B, Series A
Linear CapitalSeries B, Series A
Coatue ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    Selected to deliver late-breaking oral presentation on product GV20-0251.

  • Jun 2, 2025

    Updated Phase 1 monotherapy data for GV20-0251 presented at ASCO Annual Meeting 2025.

GV20 Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GV20 Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GV20 Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewton, Massachusetts
Employee Range19
Year Founded2016
Last FundingFeb 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?